Keymed Biosciences boosts revenue on Kangyueda push while deepening R&D pipeline

Keymed Biosciences, Inc. ( (HK:2162) ) has issued an announcement.

Keymed Biosciences reported 2025 revenue of RMB716.3 million, up 67% year on year, with gross profit rising 51% to RMB628.3 million as commercialization of its first marketed product Kangyueda accelerated, though the company still posted a loss of RMB522.6 million amid continued heavy R&D spending. Cash and equivalents fell 9% to RMB1.96 billion, but R&D expenses were broadly stable and adjusted loss only slightly widened, underscoring ongoing investment in its pipeline while improving operating leverage from rising product sales.

Commercial momentum was driven by Kangyueda, which generated about RMB315 million in 2025 sales and, from January 2026, gained inclusion for all approved indications and packaging forms in China’s National Reimbursement Drug List, significantly boosting affordability and access for patients. The company advanced multiple late-stage clinical programs, including Phase III trials for Stapokibart in adolescent and pediatric atopic dermatitis and prurigo nodularis, while partner AstraZeneca progressed several global studies of CMG901/AZD0901 in Claudin 18.2-positive gastric and other gastrointestinal cancers, reinforcing Keymed’s positioning as an emerging player in immunology and oncology biologics.

The most recent analyst rating on (HK:2162) stock is a Hold with a HK$52.00 price target. To see the full list of analyst forecasts on Keymed Biosciences, Inc. stock, see the HK:2162 Stock Forecast page.

More about Keymed Biosciences, Inc.

Keymed Biosciences Inc., incorporated in the Cayman Islands and listed in Hong Kong, operates in the biopharmaceutical industry with a focus on innovative biologic therapies. Its primary products and pipeline target immunology and oncology indications, with flagship drug Kangyueda (Stapokibart, CM310), an IL-4Rα monoclonal antibody, and CMG901/AZD0901, a Claudin 18.2 antibody-drug conjugate licensed globally to AstraZeneca for solid tumor treatment.

Average Trading Volume: 1,606,829

Technical Sentiment Signal: Hold

Current Market Cap: HK$16.16B

For detailed information about 2162 stock, go to TipRanks’ Stock Analysis page.